Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Research & Development (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Research & Development for 17 consecutive years, with $25.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 20.81% to $25.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.8 million through Dec 2025, down 5.24% year-over-year, with the annual reading at $106.8 million for FY2025, 5.82% down from the prior year.
  • Research & Development for Q4 2025 was $25.5 million at Myriad Genetics, down from $28.2 million in the prior quarter.
  • The five-year high for Research & Development was $32.2 million in Q4 2024, with the low at $18.8 million in Q3 2021.
  • Average Research & Development over 5 years is $23.8 million, with a median of $23.2 million recorded in 2021.
  • The sharpest move saw Research & Development tumbled 42.74% in 2021, then skyrocketed 53.33% in 2024.
  • Over 5 years, Research & Development stood at $20.5 million in 2021, then increased by 14.15% to $23.4 million in 2022, then dropped by 10.26% to $21.0 million in 2023, then soared by 53.33% to $32.2 million in 2024, then decreased by 20.81% to $25.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $25.5 million, $28.2 million, and $25.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.